ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2563

Modulating Myofibroblast Transition Of Human Scleroderma Fibroblasts Through Inhibition Of Rho Guanine Nucleotidase-Regulated Gene Transcription

Andrew Haak1, Pei-Suen Tsou2, Dinesh Khanna3, David A. Fox2, Scott D. Larsen4 and Richard R. Neubig5, 1Department of Pharmacology, University of Michigan Medical Center, Ann Arbor, MI, 2Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, 3University of Michigan Health System, Ann Arbor, MI, 4Vahlteich Medicinal Chemistry Core, College of Pharmacy, University of Michigan, Ann Arbor, MI, 5Department of Pharmacology & Toxicology, Michigan State University, East Lansing, MI

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Scleredema and fibroblasts

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Systemic sclerosis (SSc) or scleroderma, like many fibrotic disorders, has no effective therapy. Deposition of collagen and excess extracellular matrix depends on the transition of dermal fibroblasts into myofibroblasts. Current drug development has focused on targeting the initial inflammatory stimuli and specific receptors involved in fibrosis. Recent evidence, however, indicates that a transcriptional program regulated by Rho GTPase is critical for myofibroblast transition. This could be a more effective convergent target for interrupting pathological fibrosis regardless of the initial inflammatory or fibrotic stimulus. We recently identified novel inhibitors of this transcription mechanism including CCG-203971 (Bell et al, Bioorg Med Chem Lett. 23:3826, 2013). Here we assess their effectiveness in human SSc dermal fibroblasts.

Methods:

Primary human dermal fibroblasts were obtained from normal individuals and patients with diffuse SSc. Cells were passaged three times in DMEM containing 10% fetal bovine serum prior to studies which were carried out at passage 4 or 5. mRNA for connective tissue growth factor (CTGF), alpha-smooth muscle actin (ACTA2) and collagen type 1 alpha 1 (COL1α1) were quantified by qRT-PCR. The fraction of cells positive for the myofibroblast maker alpha-smooth muscle actin (α-SMA) was determined by immunocytochemistry. Inhibitors of Rho/MRTF/SRF-regulated gene expression (CCG-203971) and pirfenidone, the only approved antifibrotic therapy, were tested for their ability to suppress these markers of myofibroblast transition and fibrosis.

Results:

SSc dermal fibroblasts express significantly more mRNA for CTGF (3.7-fold) and ACTA2 (4.6-fold) than do normal  control fibroblasts. Similarly the percentage of cells staining positively for α-SMA was significantly greater for SSc (77±9%) than for normal (27±18%) dermal fibroblasts (p<0.001, n=6). CTGF,ACTA2, and COL1α1 mRNA in SSc fibroblasts were inhibited at 24 hours by CCG-203971 with an IC50 of ~10 μM. Treatment of SSc fibroblasts for 72 hours with 10 µM CCG-203971 reduced the percentage of α-SMA positive cells to control levels (26±18%) while pirfenidone at 300 µM was only marginally effective (41±16%). 

Conclusion:

Targeting the Rho/MRTF/SRF transcriptional pathway strongly suppresses myofibroblast activation and fibrosis-related gene expression in human SSc dermal fibroblasts. This could represent a novel targeted approach to disrupt a key genetic switch involved in fibrosis mechanisms and may provide a broad spectrum approach to treatment for systemic sclerosis and other disorders of fibrosis.


Disclosure:

A. Haak,
None;

P. S. Tsou,

Arthritis Foundation,

2;

D. Khanna,

NIH,

2,

Scleroderma Foundation,

2;

D. A. Fox,
None;

S. D. Larsen,
None;

R. R. Neubig,
None.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/modulating-myofibroblast-transition-of-human-scleroderma-fibroblasts-through-inhibition-of-rho-guanine-nucleotidase-regulated-gene-transcription/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.